Bicycle Therapeutics PLC
BCYC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761612
In the last 90 days, Bicycle Therapeutics PLC insiders filed 0 open-market purchases and 5 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $157.9M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Bicycle Therapeutics PLC insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 5 insiders, $60.5K in total
- Insiders trading
- 5
- Net value
- −$60.5K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Bicycle Therapeutics PLC, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Thompson Travis Alvin | Chief Financial Officer | 64,441 | Jul 17, 2026 | 6 |
| Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 94,375 | Jul 17, 2026 | 5 |
| Skynner Michael | CHIEF SCIENTIFIC OFFICER | 157,171 | Jul 17, 2026 | 5 |
| Perry Jennifer Scott | Chief Operating Officer | 91,052 | Jul 17, 2026 | 3 |
| Lee Kevin | CHIEF EXECUTIVE OFFICER | 603,671 | Jul 7, 2026 | 4 |
| Baker Julian | Director, 10% Owner | 10,018,674Indirect | Jan 6, 2026 | 1 |
| Baker Felix | Director, 10% Owner | 10,018,674Indirect | Jan 6, 2026 | 1 |
| Baker Bros. Advisors LP | Director, 10% Owner | 10,018,674Indirect | Jan 6, 2026 | 1 |
| Baker Brothers Life Sciences LP | Director, 10% Owner | 10,018,674Indirect | Jan 6, 2026 | 1 |
| 667, L.P. | Director, 10% Owner | 10,018,674Indirect | Jan 6, 2026 | 1 |
| Baker Bros. Advisors (GP) LLC | Director, 10% Owner | 10,018,674Indirect | Jan 6, 2026 | 1 |
| Hoppenot Herve | Director | 15,532 | Jan 6, 2026 | 1 |
| Gutierrez-Ramos Jose-Carlos | Director | 32,500 | Jan 6, 2026 | 1 |
| Dansey Roger D | Director | 15,532 | Jan 6, 2026 | 1 |
| Winter Gregory Paul | Director | 196,427 | Jan 6, 2026 | 1 |
| Bourque Janice | Director | 32,500 | Jan 6, 2026 | 1 |
| Riva Alessandro | Director | 19,880 | Jan 6, 2026 | 1 |
| Milnes Alistair | CHIEF OPERATING OFFICER | 136,717 | Jan 6, 2026 | 2 |
| Sands Stephen H. | Director | 26,893 | Jan 6, 2026 | 1 |
| Young Alethia | Chief Financial Officer | 87,081 | Jan 6, 2026 | 2 |
| Swanton Robert Charles | Director | 19,213 | Jan 6, 2026 | 2 |
| Westin Eric | Chief Medical Officer | – | Mar 27, 2025 | 0 |
| Kender Richard N | Director | 23,000 | Jan 6, 2025 | 0 |
| Legault Pierre | Director | 46,000 | Jan 6, 2025 | 0 |
| Arroyo Santiago | CHIEF DEVELOPMENT OFFICER | 69,057 | Jan 6, 2025 | 0 |
| Crockett Nigel | CHIEF BUSINESS OFFICER | 51,053 | Jan 6, 2025 | 0 |
| Keen Nicholas | CHIEF SCIENTIFIC OFFICER | 62,024 | Jul 8, 2024 | 0 |
| Jordan Veronica GH | Director | 16,750 | Jan 4, 2024 | 0 |
| Kalowski Lee | President and CFO | 30,309 | Apr 5, 2023 | 0 |
| Smethurst Dominic | Chief Medical Officer | 36,699 | Jan 5, 2023 | 0 |
| Bingham Kate | Director | 38,708Indirect | Jul 20, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 6, 2026 (view filing) | Jan 2-5 | 4 days | Lee KevinCHIEF EXECUTIVE OFFICER | SSale | −21.3K | $6.62 | −$141.2K | −3.3%619.0K after | 2 lots |
| Jan 6, 2026 (view filing) | Jan 2-5 | 4 days | Milnes AlistairCHIEF OPERATING OFFICER | SSale | −6.66K | $6.63 | −$44.1K | −4.6%136.7K after | 2 lots |
| Jan 6, 2026 (view filing) | Jan 2-5 | 4 days | Young AlethiaChief Financial Officer | SSale | −7.62K | $6.62 | −$50.5K | −8.0%87.1K after | 3 lots10b5-1 |
| Jan 6, 2026 (view filing) | Jan 2-5 | 4 days | Thompson Travis AlvinCHIEF ACCOUNTING OFFICER | SSale | −2.43K | $6.64 | −$16.1K | −3.5%66.3K after | 2 lots |
| Jan 6, 2026 (view filing) | Jan 2-5 | 4 days | Hannay Michael Charles FergusonCHIEF PROD & SUPPLY CHAIN OFF | SSale | −5.19K | $6.64 | −$34.5K | −5.0%97.9K after | 2 lots |
| Apr 6, 2026 (view filing) | Apr 2-6 | 4 days | Skynner MichaelCHIEF SCIENTIFIC OFFICER | SSale | −2.40K | $4.94 | −$11.9K | −1.5%159.6K after | 2 lots |
| Apr 6, 2026 (view filing) | Apr 2-6 | 4 days | Lee KevinCHIEF EXECUTIVE OFFICER | SSale | −7.68K | $4.94 | −$38.0K | −1.2%611.3K after | 2 lots |
| Apr 6, 2026 (view filing) | Apr 2-6 | 4 days | Thompson Travis AlvinChief Financial Officer | SSale | −901 | $4.93 | −$4.44K | −1.4%65.4K after | 2 lots |
| Apr 6, 2026 (view filing) | Apr 2-6 | 4 days | Hannay Michael Charles FergusonCHIEF PROD & SUPPLY CHAIN OFF | SSale | −1.77K | $4.93 | −$8.74K | −1.8%96.1K after | 2 lots |
| Apr 6, 2026 (view filing) | Apr 2-6 | 4 days | Perry Jennifer ScottChief Operating Officer | SSale | −1.41K | $4.94 | −$6.96K | −1.5%92.5K after | 3 lots10b5-1 |
| Jul 7, 2026 (view filing)5:00 PM ET | Jul 2-6 | 5 days | Thompson Travis AlvinChief Financial Officer | SSale | −923 | $4.27 | −$3.95K | −1.4%64.4K after | 2 lots |
| Jul 7, 2026 (view filing)5:00 PM ET | Jul 2-6 | 5 days | Hannay Michael Charles FergusonCHIEF PROD & SUPPLY CHAIN OFF | SSale | −1.76K | $4.28 | −$7.53K | −1.8%94.4K after | 2 lots |
| Jul 7, 2026 (view filing)5:00 PM ET | Jul 2-6 | 5 days | Lee KevinCHIEF EXECUTIVE OFFICER | SSale | −7.64K | $4.28 | −$32.7K | −1.3%603.7K after | 2 lots |
| Jul 7, 2026 (view filing)5:00 PM ET | Jul 2-6 | 5 days | Skynner MichaelCHIEF SCIENTIFIC OFFICER | SSale | −2.39K | $4.28 | −$10.2K | −1.5%157.2K after | 2 lots |
| Jul 7, 2026 (view filing)5:00 PM ET | Jul 2-6 | 5 days | Perry Jennifer ScottChief Operating Officer | SSale | −1.41K | $4.29 | −$6.05K | −1.5%91.1K after | 3 lots10b5-1 |